RedHill Biopharma vs Rallybio
RDHL and RLYB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RDHL and RLYB compare
Rallybio grew revenue faster over the last twelve months (−35.6% versus −96.4% for RedHill Biopharma).
Rallybio scores higher on the StockData Score (10 against 0 for RedHill Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RDHL | RLYB |
|---|---|---|
| Size and price | ||
| Market cap | – | $84.6M |
| Share price | $0.375 | $15.72 |
| Change, 1 year | −65.0% | 181% |
| Change, 5 years | −100.0% | −85.5% |
| Beta (5Y) | 1.71 | 0.64 |
| Employees | 13 | 14 |
| StockData Score | ||
| Total score | 0 | 10 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 3.4× |
| P/S | – | 195× |
| P/B | – | 0.9× |
| Growth | ||
| Revenue growth (TTM) | −96.4% | −35.6% (better) |
| Revenue growth, 5Y average | −66.2% | – |
| Profitability | ||
| Operating margin | −2777% (better) | −5581% |
| Net margin | – | 6177% |
| FCF margin | −3376% | – |
| Return on equity | – | 34.5% |
| Return on invested capital | – | −718% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −5.5× | – |
| Current ratio | 0.34 | 28.87 (better) |
| Altman Z-score | – | 11.84 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | – |
| Held by insiders | 4.4% | 72.6% |
| Insider net buying, 12 months | −$1.4K | $4.2M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 2.6% |
Go deeper
- RDHL stock overview
- RDHL income statement
- RDHL valuation and score
- RLYB stock overview
- RLYB income statement
- RLYB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.